Literature DB >> 18439425

Hepatic involvement and portal hypertension predict mortality in chronic granulomatous disease.

Jordan J Feld1, Nadeem Hussain, Elizabeth C Wright, David E Kleiner, Jay H Hoofnagle, Sushil Ahlawat, Victoria Anderson, Dianne Hilligoss, John I Gallin, T Jake Liang, Harry L Malech, Steven M Holland, Theo Heller.   

Abstract

BACKGROUND & AIMS: Chronic granulomatous disease (CGD) is a rare genetic disorder, predisposing affected individuals to recurrent infectious complications and shortened survival. Liver involvement in CGD includes vascular abnormalities, which may lead to noncirrhotic portal hypertension.
METHODS: To evaluate the impact of noncirrhotic portal hypertension on survival in CGD, all records from 194 patients followed up at the National Institutes of Health with CGD were reviewed. Cox proportional hazards regression was used to determine factors associated with mortality.
RESULTS: Twenty-four patients died, all from infectious complications. By Cox regression, factors associated with mortality were as follows: (1) decreases in platelet count (>9000/microL/y; hazard ratio, 4.7; P = .007), (2) alkaline phosphatase level increases (>0.25/y; hazard ratio, 4.5; P = .01) and (3) history of liver abscess (hazard ratio, 3.1; P = .03). By regression analysis, decreasing platelet count was associated with increasing portal vein diameter, splenomegaly, increased serum immunoglobulin G level, and increasing number of alanine aminotransferase increases; greater number of alkaline phosphatase level increases and abscess were both associated with increasing age and number of infections. Prospective evaluation revealed increased hepatic-venous pressure gradients in 2 patients with progressive thrombocytopenia, suggestive of portal hypertension.
CONCLUSIONS: These data suggest mortality in patients with CGD is associated with the development of noncirrhotic portal hypertension, likely owing to injury to the microvasculature of the liver from repeated systemic and hepatic infections. The slope of decline in platelet count may be a useful measure of progression of portal hypertension over time. Furthermore, the data illustrate the potential independent effect of portal hypertension on clinical outcome outside the setting of cirrhosis.

Entities:  

Mesh:

Year:  2008        PMID: 18439425      PMCID: PMC2583937          DOI: 10.1053/j.gastro.2008.02.081

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  39 in total

Review 1.  The hepatic venous pressure gradient: anything worth doing should be done right.

Authors:  Roberto J Groszmann; Suchat Wongcharatrawee
Journal:  Hepatology       Date:  2004-02       Impact factor: 17.425

2.  Role of ischemia in causing apoptosis, atrophy, and nodular hyperplasia in human liver.

Authors:  K Shimamatsu; I R Wanless
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

Review 3.  Chronic granulomatous disease.

Authors:  Paul G Heyworth; Andrew R Cross; John T Curnutte
Journal:  Curr Opin Immunol       Date:  2003-10       Impact factor: 7.486

4.  Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?

Authors:  F Schepis; C Cammà; D Niceforo; A Magnano; S Pallio; M Cinquegrani; G D'amico; L Pasta; A Craxì; A Saitta; G Raimondo
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

5.  Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection.

Authors:  K Watt; J Uhanova; Y Gong; K Kaita; K Doucette; N Pettigrew; G Y Minuk
Journal:  J Viral Hepat       Date:  2004-05       Impact factor: 3.728

6.  Survival of childhood polycystic kidney disease following renal transplantation: the impact of advanced hepatobiliary disease.

Authors:  Ira D Davis; Martin Ho; Vera Hupertz; Ellis D Avner
Journal:  Pediatr Transplant       Date:  2003-10

7.  The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial.

Authors:  Brindhesha Rasaratnam; David Kaye; Garry Jennings; Francis Dudley; Jaye Chin-Dusting
Journal:  Ann Intern Med       Date:  2003-08-05       Impact factor: 25.391

8.  6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.

Authors:  Marla C Dubinsky; Eric A Vasiliauskas; Hardeep Singh; Maria T Abreu; Kostas A Papadakis; Tram Tran; Paul Martin; John M Vierling; Stephen A Geller; Stephan R Targan; Fred F Poordad
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

Review 9.  Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut.

Authors:  Reiner Wiest; Heiko C Rath
Journal:  Best Pract Res Clin Gastroenterol       Date:  2003-06       Impact factor: 3.043

10.  Itraconazole to prevent fungal infections in chronic granulomatous disease.

Authors:  John I Gallin; David W Alling; Harry L Malech; Robert Wesley; Deloris Koziol; Beatriz Marciano; Eli M Eisenstein; Maria L Turner; Ellen S DeCarlo; Judith M Starling; Steven M Holland
Journal:  N Engl J Med       Date:  2003-06-12       Impact factor: 91.245

View more
  26 in total

Review 1.  Chronic granulomatous disease: overview and hematopoietic stem cell transplantation.

Authors:  Elizabeth M Kang; Betty E Marciano; SukSee DeRavin; Kol A Zarember; Steven M Holland; Harry L Malech
Journal:  J Allergy Clin Immunol       Date:  2011-04-17       Impact factor: 10.793

Review 2.  Chronic granulomatous disease.

Authors:  Steven M Holland
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

Review 3.  Chronic granulomatous disease.

Authors:  Alexander J Towbin; Ian Chaves
Journal:  Pediatr Radiol       Date:  2010-02-05

Review 4.  Inflammatory consequences of inherited disorders affecting neutrophil function.

Authors:  Mary C Dinauer
Journal:  Blood       Date:  2019-03-21       Impact factor: 22.113

Review 5.  Undiagnosed liver diseases.

Authors:  Emily Gao; Julian Hercun; Theo Heller; Sílvia Vilarinho
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

6.  Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity.

Authors:  Christopher Koh; Sasan Sakiani; Pallavi Surana; Xiongce Zhao; Jason Eccleston; David E Kleiner; David Herion; T Jake Liang; Jay H Hoofnagle; Milica Chernick; Theo Heller
Journal:  Hepatology       Date:  2017-06-26       Impact factor: 17.425

7.  Role of Allogeneic Hematopoietic Stem Cell Transplant for Chronic Granulomatous Disease (CGD): a Report of the United States Immunodeficiency Network.

Authors:  Jennifer R Yonkof; Ashish Gupta; Pingfu Fu; Elizabeth Garabedian; Jignesh Dalal
Journal:  J Clin Immunol       Date:  2019-05-20       Impact factor: 8.317

8.  The Changing Paradigm of Management of Liver Abscesses in Chronic Granulomatous Disease.

Authors:  David M Straughan; Kaitlin C McLoughlin; John E Mullinax; Beatriz E Marciano; Alexandra F Freeman; Victoria L Anderson; Gulbu Uzel; Said C Azoury; Rebecca Sorber; Humair S Quadri; Harry L Malech; Suk See DeRavin; Natasha Kamal; Christopher Koh; Christa S Zerbe; Douglas B Kuhns; John I Gallin; Theo Heller; Steven M Holland; Udo Rudloff
Journal:  Clin Infect Dis       Date:  2018-04-17       Impact factor: 9.079

9.  Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo.

Authors:  Joy X Jiang; Senthil Venugopal; Nobuko Serizawa; Xiangling Chen; Fiona Scott; Yong Li; Roger Adamson; Sridevi Devaraj; Vijay Shah; M Eric Gershwin; Scott L Friedman; Natalie J Török
Journal:  Gastroenterology       Date:  2010-06-01       Impact factor: 22.682

Review 10.  Chronic granulomatous disease.

Authors:  Steven M Holland
Journal:  Hematol Oncol Clin North Am       Date:  2012-11-22       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.